Clinical Trials · NCT06830343
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Enrollment
- 66
- Start date
- Feb 2025
- Locations
- 1 site, China
- Primary endpoint
- Incidence of AEs following single-dose administration of SYH9017 Description: